In a filing, Supernus Pharmaceuticals Inc revealed its President, CEO Khattar Jack A. unloaded Company’s shares for reported $3.03 million on Oct 09 ’25. In the deal valued at $50.57 per share,59,900 shares were sold. As a result of this transaction, Khattar Jack A. now holds 1,206,578 shares worth roughly $58.37 million.
Then, NEWHALL CHARLES W III sold 25,000 shares, generating $1,269,234 in total proceeds. Upon selling the shares at $50.77, the Director now owns 104,644 shares.
Before that, JACK A. KHATTAR bought 59,900 shares. Supernus Pharmaceuticals Inc shares valued at $2,875,200 were divested by the Director at a price of $48.00 per share.
Piper Sandler upgraded its Supernus Pharmaceuticals Inc [SUPN] rating to an Overweight from a a Neutral in a research note published recently. A number of analysts have revised their coverage, including Cantor Fitzgerald’s analysts, who increased its forecast for the stock in late July from “a Neutral” to “an Overweight”. Cantor Fitzgerald also remained covering SUPN and has decreased its forecast on February 19, 2025 with a “Neutral” recommendation from previously “an Overweight” rating. Cantor Fitzgerald started covering the stock on January 06, 2025. It rated SUPN as “an Overweight”.
Price Performance Review of SUPN
On Monday, Supernus Pharmaceuticals Inc [NASDAQ:SUPN] saw its stock fall -1.27% to $48.38. Over the last five days, the stock has gained 0.14%. Supernus Pharmaceuticals Inc shares have risen nearly 49.41% since the year began. Nevertheless, the stocks have risen 33.79% over the past one year.
How much short interest is there in Supernus Pharmaceuticals Inc?
A steep rise in short interest was recorded in Supernus Pharmaceuticals Inc stocks on 2025-09-30, growing by 0.39 million shares to a total of 5.19 million shares. Yahoo Finance data shows the prior-month short interest on 2025-08-29 was 4.8 million shares. There was a rise of 7.43%, which implies that there is a positive sentiment for the stock.
